BLAINJECTIONINJECTABLE
Approved
Dec 2021
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
YUSIMRY (adalimumab-aqvh) by Emerge Bioscience Pte. Ltd. is tumor necrosis factor receptor blocking activity [moa]. First approved in 2021.
Drug data last refreshed 44m ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
YUSIMRY (adalimumab-aqvh) is a monoclonal antibody TNF receptor blocker approved in December 2021 as a biosimilar to reference adalimumab. It is used to treat autoimmune and inflammatory conditions by blocking tumor necrosis factor signaling. The product targets patients with rheumatoid arthritis, psoriasis, Crohn's disease, and other TNF-driven inflammatory disorders.
Peak
YUSIMRY is at peak lifecycle as a newer biosimilar entrant competing in a mature, high-volume market with moderate competitive pressure, requiring focused commercial and market access teams.
Mechanism of Action
Tumor Necrosis Factor Receptor Blocking Activity
Pharmacologic Class:
Tumor Necrosis Factor Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
YUSIMRY careers focus on securing payer formulary placement, managing rebate contracts, and driving provider adoption in a biosimilar-saturated market. Roles emphasize commercial execution, payer negotiations, and patient support rather than clinical development or novel mechanism innovation.
Market Access Manager
Worked on YUSIMRY at Emerge Bioscience Pte. Ltd.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.